Breaking News
Quell Therapeutics
About Quell Therapeutics
An exciting new cell therapy immunology biotech committed to transforming patient’s lives in solid organ transplantation and auto-immune conditions.
Our company is growing and we are exciting about the future! Our vision is to become a world leader in new cell therapy and the people are at the heart of what we do. We treat our people with respect, working collaboratively across the business, taking ownership and accountability for the outcomes and results we delivery. Most of all we work with integrity to innovate and bring the best version of ourselves to the job every day.
Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases
June 9 2023
Quell Therapeutics, a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions […]
Quell Therapeutics Appoints Luke Devey, BMBCh, Ph.D. as Chief Medical Officer
November 21 2022
Quell Therapeutics Ltd, a world leader in developing engineered T-regulatory (Treg) cell therapies for serious […]
Quell Therapeutics and Cellistic™ Enter a Strategic Collaboration to Develop an iPSC-derived Allogeneic T-regulatory (Treg) Cell Therapy Platform
April 27 2022
Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious […]
Quell Therapeutics Raises $156 Million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform
November 29 2021
Quell Therapeutics Ltd (“Quell”), the world leader in the development of engineered T-regulatory (Treg) cell […]
Quell Therapeutics Granted CTA Approval to Begin First Clinical Trial with a Multi-modular Engineered Treg Cell Therapy
October 27 2021
Quell Therapeutics Ltd (“Quell“), the world leader in developing engineered T-regulatory (Treg) cell therapies for […]
Quell Therapeutics Appoints Dominik Hartl, M.D., as Chief Medical Officer
July 22 2021
Quell Therapeutics Ltd (“Quell”), the world leader in developing engineered T-regulatory (Treg) cell therapies for […]